Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Volume: 15, Issue: 1, Pages: 13 - 30
Published: Sep 26, 2017
Abstract
TP53, which encodes the tumour-suppressor protein p53, is the most frequently mutated gene across all cancer types. The presence of mutant p53 predisposes to cancer development, promotes the survival of cancer cells, and is associated with ineffective therapeutic responses and unfavourable prognoses. Despite these effects, no drug that abrogates the oncogenic functions of mutant p53 has yet been approved for the treatment of cancer. Current...
Paper Details
Title
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Published Date
Sep 26, 2017
Volume
15
Issue
1
Pages
13 - 30
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.